Admin

Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review

Author List
Andrew Hill
Polly Clayden
Claire Thorne
Rachel Christie
Rebecca Zash

Abstract

The integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) is recommended as an alternative first-line HIV treatment to efavirenz (EFV) in the current World Health Organization (WHO) consolidated antiretroviral (ARV) guidelines, and is widely recommended in other international treatment guidelines.

Article Category

HIV Treatment

Article Type

Original research

Posted Date

29-03-2018

Tables & Figures

Back to top